These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35246235)

  • 41. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
    Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM
    Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease.
    Kelly K; Rasko JEJ
    Front Immunol; 2021; 12():761616. PubMed ID: 34764962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation.
    Zhao K; Liu Q
    J Hematol Oncol; 2016 May; 9(1):46. PubMed ID: 27193054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation.
    Le Blanc K; Ringdén O
    Biol Blood Marrow Transplant; 2005 May; 11(5):321-34. PubMed ID: 15846285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity.
    Copland IB; Qayed M; Garcia MA; Galipeau J; Waller EK
    Biol Blood Marrow Transplant; 2015 May; 21(5):934-40. PubMed ID: 25659882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD.
    Mendt M; Daher M; Basar R; Shanley M; Kumar B; Wei Inng FL; Acharya S; Shaim H; Fowlkes N; Tran JP; Gokdemir E; Uprety N; Nunez-Cortes AK; Ensley E; Mai T; Kerbauy LN; Melo-Garcia L; Lin P; Shen Y; Mohanty V; Lu J; Li S; Nandivada V; Wang J; Banerjee P; Reyes-Silva F; Liu E; Ang S; Gilbert A; Li Y; Wan X; Gu J; Zhao M; Baran N; Muniz-Feliciano L; Wilson J; Kaur I; Gagea M; Konopleva M; Marin D; Tang G; Chen K; Champlin R; Rezvani K; Shpall EJ
    Front Immunol; 2021; 12():631353. PubMed ID: 34017325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.
    Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D;
    Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease.
    Kim Y; Jin HJ; Heo J; Ju H; Lee HY; Kim S; Lee S; Lim J; Jeong SY; Kwon J; Kim M; Choi SJ; Oh W; Yang YS; Hwang HH; Yu HY; Ryu CM; Jeon HB; Shin DM
    Leukemia; 2018 Dec; 32(12):2672-2684. PubMed ID: 29789652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.
    Yin F; Battiwalla M; Ito S; Feng X; Chinian F; Melenhorst JJ; Koklanaris E; Sabatino M; Stroncek D; Samsel L; Klotz J; Hensel NF; Robey PG; Barrett AJ
    Stem Cells; 2014 May; 32(5):1278-88. PubMed ID: 24452962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel study on the immunomodulatory effect of umbilical cord derived mesenchymal stem cells pretreated with traditional Chinese medicine Asarinin.
    He H; Yang T; Li F; Zhang L; Ling X
    Int Immunopharmacol; 2021 Nov; 100():108054. PubMed ID: 34492537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation.
    Kim EJ; Kim N; Cho SG
    Exp Mol Med; 2013 Jan; 45(1):e2. PubMed ID: 23306700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers.
    Cheung TS; Bertolino GM; Giacomini C; Bornhäuser M; Dazzi F; Galleu A
    Front Immunol; 2020; 11():1338. PubMed ID: 32670295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Multipotent mesenchymal stromal cells application for acute graft versus host disease treatment].
    Kuzmina LA; Petinati NA; Vasilieva VA; Dovydenko MV; Drokov MY; Davydova YO; Kapranov NM; Sats NV; Chabaeva YA; Kulikov SM; Gaponova TV; Drize NI; Parovichnikova EN; Savchenko VG
    Ter Arkh; 2020 Sep; 92(7):23-30. PubMed ID: 33346442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.
    Mielcarek M; Storb R; Georges GE; Golubev L; Nikitine A; Hwang B; Nash RA; Torok-Storb B
    Biol Blood Marrow Transplant; 2011 Feb; 17(2):214-25. PubMed ID: 20816818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease.
    Tang B; Li X; Liu Y; Chen X; Li X; Chu Y; Zhu H; Liu W; Xu F; Zhou F; Zhang Y
    Cell Physiol Biochem; 2018; 46(6):2624-2635. PubMed ID: 29763906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study.
    Jurado M; De La Mata C; Ruiz-García A; López-Fernández E; Espinosa O; Remigia MJ; Moratalla L; Goterris R; García-Martín P; Ruiz-Cabello F; Garzón S; Pascual MJ; Espigado I; Solano C
    Cytotherapy; 2017 Aug; 19(8):927-936. PubMed ID: 28662983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Current basic understanding and clinical application of mesenchymal stromal/stem cells].
    Miura Y
    Rinsho Ketsueki; 2018; 59(10):1935-1941. PubMed ID: 30305494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results.
    Liu Z; Zhang Y; Xiao H; Yao Z; Zhang H; Liu Q; Wu B; Nie D; Li Y; Pang Y; Fan Z; Li L; Jiang Z; Duan F; Li H; Zhang P; Gao Y; Ouyang L; Yue C; Xie M; Shi C; Xiao Y; Wang S
    Bone Marrow Transplant; 2017 May; 52(5):704-710. PubMed ID: 28067873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
    J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats.
    Kitazawa Y; Li XK; Xie L; Zhu P; Kimura H; Takahara S
    Cell Transplant; 2012; 21(2-3):581-90. PubMed ID: 22793067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.